Join
Live feed
·
PRReleasevia Quantisnow
Cara Therapeutics Inc. logo

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

ByQuantisnow·Wall Street's wire, on your screen.
CARA· Cara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CARA (Cara Therapeutics Inc.) and more on Quantisnow.